Advanced Viral Research Corp. Announces the Appointment of Dr. Raymond Tudor as Vice President for Drug Development.Business/Medical Editors YONKERS, N.Y.--(BUSINESS WIRE)--Aug. 7, 2001 Advanced Viral Research Corp. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : ADVR ADVR Association of Directors of Volunteer Resources (Canada) ) today announced the appointment of Dr. Raymond Tudor as Vice President for Drug Development. In his new capacity, Dr. Tudor will be responsible for advancing Product R through the regulatory processes into worldwide markets. Product R, the lead drug of ADVR, is a non-toxic peptide-nucleic acid immunomodulator. Dr. Tudor has thirty years of experience in the international pharmaceutical industry and has been responsible for the development and marketing of a variety of prescription drugs. Prior to joining ADVR, Dr. Tudor served as Vice President for International Technical Services at Schein Pharmaceutical, Inc. where he was responsible for all technical aspects of Schein's international business. He also served as Director of International Regulatory Affairs at Schein Bayer Pharmaceutical Services Inc. Previously, Dr. Tudor spent fifteen years with Sanofi Pharmaceuticals Inc. in various managerial positions. "We are extremely pleased that Dr. Raymond Tudor has joined us at this important juncture in the history of our Company. His appointment is a further step in the formation of the management team that will exploit the therapeutic potential of Product R," stated Shalom Z. Hirschman, MD, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Advanced Viral Research Corp. "Dr. Tudor brings to the Company a career track record of successfully launching new drugs through the regulatory and business processes. His expertise encompasses all aspects of strategic direction including pharmaceutical alliances, product positioning and marketing." PRODUCT R is a non-toxic peptide nucleic acid-type immunomodulator that appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus human papilloma virus n. Abbr. HPV A DNA virus of the genus Papillomavirus, certain types of which cause cutaneous and genital warts in humans, including condyloma acuminatum. and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. . Therefore, Product R has been termed a "switch type" immunomodulator. Product R has direct antiviral effects against select viruses such as adenovirus adenovirus Any of a group of spheroidal viruses, made up of DNA wrapped in a protein coat, that cause sore throat and fever in humans, hepatitis in dogs, and several diseases in fowl, mice, cattle, pigs, and monkeys. and human papillomavirus. Product R has shown promise in its ability to mitigate the toxic side effects of other drugs, including those used to treat HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. infection and chemotherapeutic drugs employed in the treatment of cancers. Advanced Viral Research Corp., based in Yonkers, New York Yonkers is the fourth largest city in the State of New York (it falls behind New York City, Buffalo, and Rochester), and the largest city in Westchester County, with a population of 196,086 (according to the 2000 census). , is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Product R is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. ADVR undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion